India’s life sciences sector is rapidly expanding, driven by a combination of government initiatives, demographic trends, and global demand according to a recent report.
India’s “bioeconomy”, valued is projected to reach $150 billion in 2025, with ambitions to hit $300 billion by 2030. This growth is fueled by sub-sectors such as pharmaceuticals, biotechnology, and medical devices, which are increasingly contributing to both domestic healthcare and global exports.
Key drivers include:
– Rising healthcare needs due to an aging and growing population.
– A skilled workforce comprising scientists, engineers, and healthcare professionals, which has attracted international companies to set up R&D centers in India.
– Government policies such as Make in India, Pharma Vision, and the National Biotechnology Development Strategy, which have created a favorable regulatory and investment environment.
– Cost-effectiveness, making India a competitive destination for manufacturing and innovation.
India is becoming a hub for clinical trials and R&D, and that the COVID-19 pandemic underscored the importance of diversifying supply chains — boosting India’s appeal as part of the “China Plus One” strategy.
India’s life sciences sector has experienced a dramatic investment cycle over the past five years, drawing in $1.9 billion in total funding. According to the newly released “India Life Sciences Startup Investing Report – A Five-Year Review,” the sector peaked in 2022, securing $749 million, but saw a drop to $269 million by 2024, reflecting investor caution amid global economic headwinds.
Unveiled during BioWave — a platform promoting India’s bioeconomy — the report captures the evolving dynamics of this vibrant startup ecosystem. Co-authored by Omnivore, a venture capital firm focused on sustainability, and Nucleate, a biotech accelerator, the report highlights both growth and emerging vulnerabilities.
At the core of their message: continued, stable funding is essential to realize India’s potential as a leader in bioscience innovation, particularly in areas tied to climate resilience, public health, and food security. Despite recent downturns, bioscience entrepreneurship remains critical to advancing sustainable development goals.
While biopharma and medical biotechnology continue to dominate, attracting 42% of total capital, the report signals a clear shift toward emerging verticals. Investments in agrifood life sciences, sustainable materials, and industrial biotech have risen dramatically—from just $11.5 million in 2020 to $174 million by 2024. This diversification reflects growing recognition of the economic and environmental value of these sectors.
India’s life sciences sector is not only growing in scale but also evolving into a global innovation and manufacturing powerhouse, thanks to strategic policy support and a robust talent pool.
Last updated: December 26th, 2025
